RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, >>> they are not going to waste RD1 on a pre-Labor Day weekend release. <<<

Of course that assumes good results. If the results are murky or outright bad, then releasing them pre-Labor Day would be preferred.

We're less likely to have statistical significance in RD-1 for several reasons - 1) the lower dose used (1500 mg in RD-1 vrs 2100 mg in RD-2), and 2) the potential for procedural problems cropping up again, if not in the majority of subjects then in enough to prevent stat sig from being reached.

Without statistical significance in RD efficacy at 1500 mg, the press release will need to emphasize the good maintenance of analgesia seen in the subjects who did experience RD efficacy. That's the most likely outcome IMO -- no statistical significance in RD efficacy at 1500 mg (due to the dose being lower, procedural problems, or some combination), but good maint of analgesia in those who did show RD efficacy.